“Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+” (2011) Farmeconomia. Health Economics and Therapeutic Pathways, 12(2), pp. 77–85. doi:10.7175/fe.v12i2.73.